A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. 1995

E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
Department of Biochemistry, Rush Medical University at Rush-Presbyterian St. Luke's Medical Center, Chicago, IL 60612, USA.

Aggrecan, the high buoyant density cartilage proteoglycan (PG), has been shown to induce progressive polyarthritis and ankylosing spondylitis in genetically susceptible BALB/c mice. To further characterize the nature of the autopathogenic effector T cells operating in these mice and to determine the region(s) of the PG molecule recognized by these T cells, we generated PG-specific T cell hybridomas from arthritic mice. One of the PG-specific T cell hybridomas (5/4E8), when injected into naive irradiated BALB/c mice, was capable of inducing clinical and histopathologic signs of arthritis. Massive swelling and redness of the paws dominated the clinical picture. A reactive synovial cell proliferation, the accumulation of hybridoma and inflammatory cells in the enlarged joint space, the loss of PG from the superficial layer of the articular cartilage, and the erosion of articular surface were identical histopathologic signs to those found either in primary or adoptive transfer of PG-induced arthritis. The PG-specific and arthritogenic T cell hybridoma (5/4E8) expressed TCR-alpha beta + (V beta 4), CD4+, and CD8- phenotypes and belonged to the Th1 subset, as the cells secreted IL-2 and IFN-gamma, but not IL-4 upon PG stimulation, and the response was MHC class II (I-Ad)-restricted. These observations provide direct evidence that PG-specific Th cells play crucial roles in autoimmune arthritic processes.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D005260 Female Females
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D001168 Arthritis Acute or chronic inflammation of JOINTS. Oligoarthritis,Polyarthritis,Arthritides,Oligoarthritides,Polyarthritides
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
April 2013, Immunology letters,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
May 2011, Arthritis and rheumatism,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
November 1999, Journal of immunology (Baltimore, Md. : 1950),
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
May 1997, Biochemical Society transactions,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
January 1996, American journal of therapeutics,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
April 1998, The Journal of clinical investigation,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
February 1987, Arthritis and rheumatism,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
June 2005, Cellular immunology,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
August 2006, Arthritis and rheumatism,
E I Buzás, and F R Brennan, and K Mikecz, and M Garzó, and G Negroiu, and K Holló, and G Cs-Szabó, and E Pintye, and T T Glant
January 2014, BioMed research international,
Copied contents to your clipboard!